Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Post by TechMooseon Apr 18, 2023 1:34pm
398 Views
Post# 35401053

Antibe Director to Leave Position (As CEO of MaRS)

Antibe Director to Leave Position (As CEO of MaRS) Call me an eternal optimist, but I am wondering if Yung Wu's upcoming departure may open up a window for Antibe to step out more and drive visibility.  He's a proven operator.  Smart, high energy and has a demonstrated track record.  Previously as an entrepreneur he sold his company to Oracle and made a lot of money.  

He currently sits on the ATE board and is a major shareholder of ATE.  No doubt he's seriously frustrated by the share price and has been asking questions.  He's driven and I am sure has wanted to see more progress and a move to NASDAQ.  

Press release on his departure is here.  Succession process for such a specialized role as this is a 1 year search process so they have to do this well in advance.   
https://www.marsdd.com/media-centre/mars-discovery-district-ceo-yung-wu-extending-his-five-year-service-commitment-an-extra-year/

Having Yung Wu step up into a more hands on role would be a VERY good thing for ATE.  Just sayin'
Dan and the management team should be paying close attention to this...


<< Previous
Bullboard Posts
Next >>